Explore

Rapid ReadRapid Read
Representative Jake Auchincloss Introduces 'Faster Clinical Trials Act' to Modernize Drug Development

Representative Jake Auchincloss Introduces 'Faster Clinical Trials Act' to Modernize Drug Development

U.S. Rep. Jake Auchincloss, D-Mass., has introduced H.R. 10857, known as the 'Faster Clinical Trials Act.' This comprehensive bill aims to accelerate medical research, enhance clinical trial efficiency, and strengthen oversight in drug development and labeling. Key provisions include establishing an FDA-led 'Cures in Care' program to facilitate routine clinical trials within standard healthcare settings, promoting decentralized methods, and prioritizing underserved populations. The bill also mandates more standardized data sharing for point-of-care trials, expands FDA and CMS guidance on trial funding, and updates oversight rules. Furthermore, it seeks to modernize the review of early-stage trials, align with international standards, and scrutinize foreign data used in FDA decisions. The legislation also proposes creating an FDA Rare Disease Innovation Hub to expedite rare disease trials and biomarker development. Additionally, it would establish an Oncology Center of Excellence and a new FDA process for r...
Rapid ReadRapid Read
Gene Therapy for Rare Diseases Dominates Approved Products and Clinical Trials

Gene Therapy for Rare Diseases Dominates Approved Products and Clinical Trials

A recent cross-sectional registry analysis has revealed that rare disorders account for 80% of approved gene therapy products and over 44% of all registered gene therapy clinical trials. The study, which analyzed 1,464 registered clinical investigations, identified 646 studies specifically targeting rare conditions, spanning 175 distinct rare diseases. The findings indicate a substantial and sustained growth in rare disease research over the past decade, with annual trial initiations more than tripling from 21 in 2015 to 73 in 2024. The research team integrated data from multiple public registries, including the United States Food and Drug Administration (FDA), Orphanet, and ClinicalTrials.gov. Of the 30 FDA-approved gene therapy products, 24 (80%) carried at least one rare disease indication, covering 16 distinct rare diseases. Despite this progress, early-phase trials still constitute nearly two-thirds of the investigational pipeline, and there is a significant geographic concentration of trials, with th...
Rapid ReadRapid Read
Aravax Announces Positive Phase 2 Trial Results for Peanut Allergy Immunotherapy PVX108 in US and Australia

Aravax Announces Positive Phase 2 Trial Results for Peanut Allergy Immunotherapy PVX108 in US and Australia

Aravax, a clinical-stage biotechnology company, has announced positive topline results from its Phase 2 clinical trial of PVX108, a novel immunotherapy for peanut allergy. The trial, conducted across 14 sites in the US and Australia, involved children aged 4 to 11 years. PVX108 is designed to retrain the immune system to tolerate peanuts while minimizing acute allergic reactions. The study met its primary efficacy endpoint, showing a statistically significant increase in the maximum tolerated dose of peanut in participants treated with PVX108 compared to placebo. Additionally, a significant reduction in the severity of food challenge reactions and an improvement in the emotional impact of living with a food allergy were observed. The treatment was well-tolerated, with no treatment-related allergic adverse events or serious adverse events reported. These results will be presented at the Annual Scientific Meeting of the American College of Allergy, Asthma and Immunology (ACAAI) in Phoenix, AZ.
TrendlineTrendline
FDA Sets Target Action Dates for Five Biotech Companies' Drug Applications

FDA Sets Target Action Dates for Five Biotech Companies' Drug Applications

FDA Sets Target Action Dates for Five Biotech Companies' Drug Applications
TrendlineTrendline
Fresenius and WuXi Biologics Announce Exclusive Agreement to Expand Biosimilars Pipeline

Fresenius and WuXi Biologics Announce Exclusive Agreement to Expand Biosimilars Pipeline

Fresenius and WuXi Biologics Announce Exclusive Agreement to Expand Biosimilars Pipeline
Rapid ReadRapid Read
African Institutions Urged to Lead Antimicrobial Resistance Research, Shape Next-Gen Antibiotics and Diagnostics

African Institutions Urged to Lead Antimicrobial Resistance Research, Shape Next-Gen Antibiotics and Diagnostics

African institutions are called upon to play a leading role in antimicrobial resistance (AMR) research, influencing the development and testing of next-generation antibiotics and diagnostics. The World Health Organization's 2025 assessments highlighted ongoing gaps in antibacterial innovation, pediatric formulations, and oral treatments, as well as limited simple diagnostic tools for primary and secondary care. The article emphasizes that surveillance data, such as that from Kenya and Rwanda's expanded Global Antimicrobial Resistance and Use Surveillance System (GLASS), should inform target product profiles for new medical tools. It advocates for African institutions to help define research questions, select meaningful outcomes, and interpret site-specific differences, ensuring that new products are designed for the conditions in which they will be used.
AP NewsAP News
Trump administration will fund new research on controversial psychedelic drug ibogaine

Trump administration will fund new research on controversial psychedelic drug ibogaine

Federal officials say there's new funding to study the medical potential of a powerful psychedelic
Rapid ReadRapid Read
United States Leads Global CRISPR Gene Editing Trials with 356 Studies Underway

United States Leads Global CRISPR Gene Editing Trials with 356 Studies Underway

The United States is at the forefront of CRISPR gene editing research, leading globally in the number of clinical trials. According to the CMN Clinical Trials Q3 2026 Global Report, there are 356 gene-editing trials worldwide as of September 30, 2026. The U.S. and China collectively account for the majority of these trials, with other significant contributions from Australia, the United Kingdom, Canada, and New Zealand. This report, compiled by CMN Intelligence, utilizes a manually curated global database of clinical gene-editing trials to provide a comprehensive overview of the landscape. The data also delves into various aspects of these trials, including editing approaches, cell sources, and delivery technologies being employed across the global clinical gene-editing landscape. This robust activity signifies a rapid advancement in the application of gene-editing technologies for therapeutic purposes.
Rapid ReadRapid Read
FDA Clears Metagenomi's IND for MGX-001, a One-Time Genome Editing Therapy for Hemophilia A

FDA Clears Metagenomi's IND for MGX-001, a One-Time Genome Editing Therapy for Hemophilia A

The FDA has cleared Metagenomi Therapeutics' Investigational New Drug (IND) application for MGX-001, its lead genome editing program for hemophilia A. This clearance allows the company to initiate a first-in-human Phase 1/2 trial for the one-time therapy in adults and children with moderately severe to severe hemophilia A. MGX-001 is designed to site-specifically integrate the Factor VIII (FVIII) gene into a 'safe harbor' location within the albumin gene, utilizing the body's native albumin promoter to drive durable, endogenous FVIII production. The therapy uses an adeno-associated virus (AAV) vector for the FVIII gene cassette and a lipid nanoparticle (LNP) to deliver mRNA encoding a proprietary Type V CRISPR nuclease.
TrendlineTrendline
BridgeBio Pharma to Present Extensive New Data on Acoramidis for ATTR-CM at International Symposium

BridgeBio Pharma to Present Extensive New Data on Acoramidis for ATTR-CM at International Symposium

BridgeBio Pharma to Present Extensive New Data on Acoramidis for ATTR-CM at International Symposium
TrendlineTrendline
SeaStar Medical Reports Strong Q3 2026 Revenue Growth, Updates NEUTRALIZE-AKI Trial Timeline

SeaStar Medical Reports Strong Q3 2026 Revenue Growth, Updates NEUTRALIZE-AKI Trial Timeline

SeaStar Medical Reports Strong Q3 2026 Revenue Growth, Updates NEUTRALIZE-AKI Trial Timeline
Rapid ReadRapid Read
FDA CBER Holds Listening Meeting on Early Enrollment in Gene Therapy Trials for Rare Diseases

FDA CBER Holds Listening Meeting on Early Enrollment in Gene Therapy Trials for Rare Diseases

The FDA Center for Biologics Evaluation and Research (CBER) hosted a public listening meeting on December 4, 2024, to gather perspectives from patients and care partners regarding early enrollment in gene therapy clinical trials for rare diseases. The meeting aimed to understand the considerations individuals and families weigh when deciding whether to participate in trials during pre-symptomatic or early symptomatic stages of a genetic disease. Rare genetic diseases can manifest at various life stages, and their progression and symptom severity can differ significantly even among individuals with the same genetic mutation. The objective was to explore what information and factors influence the decision to enroll in investigational gene therapy trials, particularly concerning the potential to prevent or slow disease progression or delay onset. The meeting was divided into two sessions, focusing on early enrollment for children and adults, respectively. In conjunction with the meeting, the FDA also opened a...